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Myxoma virus, a rabbit poxvirus, can efficiently infect
various classes of mouse and human cancer cells. It is a
strict rabbit-specific pathogen, safe to use in all non-rabbit
hosts tested including mice and humans. Recombinant
viruses were previously engineered to express tdToma-
toRed fluorescent protein (vMyx-tdTr) and mouse
interleukin-15 (vMyx-IL15-tdTr). IL15 is an immuno-
modulatory cytokine with a great potential for stimulating
T lymphocytes and NK cells. It has been shown that coex-
pression of IL15 with the a subunit of IL15 receptor
(IL15Ra) greatly enhances IL15 stability and bioavail-
ability. Our previous studies have shown that earlier gen-
eration recombinant myxoma viruses (vMyx-tdTr and
vMyx-IL15-tdTr) selectively infected tumors, but had
limited therapeutic effect in vivo. In order to use myxoma
virus as a vehicle to deliver immuno-stimulatory cytokine
to tumors, we engineered a new recombinant myxoma
virus (vMyx-IL15Ra-tdTr), which expresses IL15Ra-IL15
fusion protein and tdTomatoRed fluorescent protein.
Multi-step growth curves show productive infection of
various cancer cell lines tested. Melanoma (B16-F10 and
B16.SIY) and glioma (GL261 and GL261.SIY) cell lines are
permissive to myxoma infection. RK-13 cells infected with
vMyx-IL15Ra-tdTr (MOI=5) express and secrete the
IL15Ra-IL15 fusion protein. Functional activity of the
secreted fusion protein in vitro is confirmed by stimulating
proliferation of the cytokine-dependent CTLL-2 cells.
In vivo experiments, in which RAG-/- mice with subcuta-
neous B16-F10 tumors were treated twice inratumorally
with 2.6x107 ffu vMyx-IL15Ra-tdTr, showed a significant
survival benefit for the treated group compared to the PBS
control and the control virus (vMyx-tdTr). Fusion-protein
expressing virus attenuated tumor growth and prolonged
survival (median survival of 29, 23 and 17 days for vMyx-
IL15Ra-tdTr, vMyx-tdTr and PBS treated groups, respec-
tively). Immunohostological analysis of the subcutaneous
tumors showed dramatically increased infiltration of NK
cells in vMyx-IL15Ra-tdTr treated tumors compared to
both controls. We hypothesized that the three virotherapeu-
tic effects of the virus (oncolysis, delivery of IL15Ra-IL15,
and immune activation from Toll like receptor-mediated
inflammation) will augment the antitumor activities
of host’s immune system. Our results suggest that IL15Ra-
IL15 component does improve therapeutic effect over virus
alone and that the effect is likely mediated by NK cell
component of the immune system.
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